Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management ... investigated by the Federal Trade Commission (FTC).

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... The Pharmaceutical Care Management Association, the largest ...

The largest pharmacy-benefit managers hiked ... vice president of the Pharmaceutical Care Management Association, a trade association representing PBMs. The FTC analyzed data submitted by the ...

were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty generic drugs, according to a new ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.